Literature DB >> 7333060

Disposition of antipyrine and phenytoin correlated with age and liver volume in man.

B Bach, J M Hansen, J P Kampmann, S N Rasmussen, L Skovsted.   

Abstract

The half-life and metabolic clearance rate (MCR) of antipyrine and phenytoin were determined in 14 young (mean age: 28.8 +/- 8.3 (SD) years] and in 14 elderly [mean age: 83.5 +/- 7.1 (SD) years] subjects and correlated with liver volume, which was determined by ultrasonic scanning, to see if an age-dependent difference in drug metabolism could be explained by a reduced liver weight with age. The size of the liver was smaller in the elderly subjects even when related to decreased body surface. A significant decrease in serum albumin in the elderly compared with the younger group was also noted. The half-life of antipyrine was significantly longer in the elderly than in the younger group, 756 +/- 318 and 465 +/- 110 minutes, respectively, and the MCR was correspondingly lower in the elderly even when calculated per litre of live volume, 22.8 +/- 7.8 and 36.3 +/- 8.9ml/minute/L liver volume, respectively. No significant differences in the 2 age groups were found in half-life and total clearance of phenytoin, but a reduced free phenytoin clearance was demonstrated in the elderly (240 +/- 92ml/minute/L liver volume) compared with the younger (325 +/- 81ml/minute/L liver volume) group. No significant correlation was found between liver volume and the half-life of antipyrine and phenytoin. However, a significant correlation was demonstrated between liver volume and MCR of antipyrine as well as between total and free clearance of phenytoin. No correlation was found between the half-lives of the 2 drugs, while a significant correlation existed between the clearance values. It is suggested that the age-dependent reduction in drug clearance is due not only to a smaller liver volume, but it also a result of a reduced capacity of the liver microsomes per unit of liver in the elderly. With regard to age-dependent changes in drug metabolism, the protein binding of the actual drug has to be taken into consideration.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7333060     DOI: 10.2165/00003088-198106050-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  31 in total

1.  VARIATION IN THE ACTIVITY OF LIVER MICROSOMAL DRUG-METABOLIZING ENZYMES IN RATS IN RELATION TO THE AGE.

Authors:  R KATO; P VASSANELLI; G FRONTINO; E CHIESARA
Journal:  Biochem Pharmacol       Date:  1964-07       Impact factor: 5.858

2.  Pharmacokinetics in the elderly.

Authors:  E J Triggs; R L Nation; A Long; J J Ashley
Journal:  Eur J Clin Pharmacol       Date:  1975       Impact factor: 2.953

3.  Dicoumarol-induced diphenylhydantoin intoxication.

Authors:  J M Hansen; M Kristensen; L Skovsted; L K Christensen
Journal:  Lancet       Date:  1966-07-30       Impact factor: 79.321

4.  The pharmacokinetics of acetanilide and of diphenylhydantoin sodium.

Authors:  J L Cunningham; M F Bullen; D A Evans
Journal:  Eur J Clin Pharmacol       Date:  1974-10-04       Impact factor: 2.953

5.  Genetic control of dicumarol levels in man.

Authors:  E S Vesell; J G Page
Journal:  J Clin Invest       Date:  1968-12       Impact factor: 14.808

6.  Age changes in the human liver of the different races.

Authors:  T Sato; T Miwa; H Tauchi
Journal:  Gerontologia       Date:  1970

7.  Kinetics of propylthiouracil in the elderly.

Authors:  J P Kampmann; H B Mortensen; B Bach; S Waldorff; M B Kristensen; J M Hansen
Journal:  Acta Med Scand Suppl       Date:  1979

8.  Liver volume determination by ultrasonic scanning.

Authors:  S N Rasmussen
Journal:  Dan Med Bull       Date:  1978-01

9.  Comparative drug elimination in man-diphenylhydantoin and amobarbital.

Authors:  J F Brien; T Inaba; W Kalow
Journal:  Eur J Clin Pharmacol       Date:  1975-10-10       Impact factor: 2.953

10.  The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man.

Authors:  C J Roberts; L Jackson; M Halliwell; R A Branch
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

View more
  35 in total

Review 1.  Body surface area as a determinant of pharmacokinetics and drug dosing.

Authors:  M Sawyer; M J Ratain
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

Review 2.  Pharmacokinetic considerations in the treatment of childhood epilepsy.

Authors:  Jamie T Gilman; Michael Duchowny; Ana E Campo
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 3.  Drug metabolism and ageing.

Authors:  M T Kinirons; M S O'Mahony
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

Review 4.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

5.  The 'apparent clearance' of free phenytoin in elderly vs. younger adults.

Authors:  Daniel F B Wright; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

6.  Applying organ clearance concepts in a clinical setting.

Authors:  Jorge Duconge
Journal:  Am J Pharm Educ       Date:  2008-10-15       Impact factor: 2.047

7.  Relationships among liver and kidney volumes, lean body mass and drug clearance.

Authors:  S Nawaratne; J E Brien; E Seeman; R Fabiny; J Zalcberg; W Cosolo; P Angus; D J Morgan
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

Review 8.  Pharmacokinetic and pharmacodynamic changes in the elderly. Clinical implications.

Authors:  A Hämmerlein; H Derendorf; D T Lowenthal
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

Review 9.  Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.

Authors:  James H Fischer; Tejal V Patel; Patricia A Fischer
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 10.  Drug treatment of epilepsy in elderly people: focus on valproic Acid.

Authors:  Linda J Stephen
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.